Introduction
Insulin-like growth factor I (IGF-I) has been shown to rescue Alzheimer's disease (AD) pathology in mouse models, 1 whereas IGF-I signaling is decreased in human AD. 2 Conversely, hemizygous ablation of the IGF-I receptor or full elimination of the neuronal IGF-I receptor protected against AD pathology in mice and worms. 3, 4 Therefore, the role of IGF-I in AD is controversial.
Insulin-like growth factor I blocks inflammatory cascades in astrocytes by activating the phosphatase calcineurin. 5 Furthermore, expression of constitutively active calcineurin in astrocytes substantially diminished neurodegeneration after injury-associated inflammation in mice. 6 Intriguingly, inflammatory cytokines such as tumor necrosis factor-a (TNFa) also stimulate calcineurin in astrocytes, which suggests a dual role of this phosphatase in astrocyte inflammatory signaling. 6 In this regard, inflammation was pointed out several years ago as a potential player in AD, 7 whereas a crucial role in the disease has more recently been postulated. 8 It is widely held that inflammation is an important secondary event in most neurodegenerative processes, including the pathological cascade set in motion by amyloidosis, the most favored etiological mechanism yet proposed for AD. 9 Indeed, a role of inflammation in AD amyloidosis is supported by multiple observations, with microglial cytokines such as TNFa having a central role in the process. 10 In this study, we examined the mechanisms underlying regulation of astrocyte calcineurin by TNFa and IGF-I and its impact on AD pathology. We found an antagonistic recruitment of the transcription factors Foxo3 and peroxisome proliferator-activated receptor-g (PPARg) onto calcineurin by TNFa and IGF-I, respectively, which greatly affects the disease in AD mice. This pathway is present in human AD brains and therefore its modulation with IGF-I may open a new therapeutic opportunity for this disease.
Materials and methods

Generation of mice and in vivo experiments
The APP/PS1 mouse modeling AD pathology was a gift from P Mouton (NIH, Bethesda, MD, USA). The 'tet-off' AIC (astrocyte-inducible calcineurin) mouse was generated as described using a murine glial fibrillary acidic protein (GFAP) promoter to drive expression of constitutively active calcineurin in astrocytes. 6 The expression of calcineurin was regulated by doxycycline (dox, Sigma, St Louis, MO, USA, 2 mg ml À1 in tap water). Only astrocytes expressed DCnA in AIC mice in response to dox. Although AIC neurons express endogenous CnA, neither microglia nor oligodendroglia showed detectable levels of CnA by western blot (Supplementary Figure 1) . Homozygous APP/PS1 mice were crossed with homozygous AIC mice to obtain the compound AICAP strain. AICAP mice maintained with dox in drinking water to restrain calcineurin expression showed a brain phenotype indistinguishable of APP/PS1 mice (see the 'Results' section). Quantification of mutant human APP and PS1 mRNAs in APP/PS1, AICAP and AICAP þ dox mice by quantitative PCR showed similar levels of expression in the three types of mice. APP/PS1 mice (7 months of age, n = 10) were treated with a subcutaneous IGF-I microsphere preparation as described previously 11 at a dose of 50 mg kg À1 per day administered every 3 weeks for 3 months.
Immunocytochemistry Immunocytochemistry was performed as described previously.
6 Animals (n = 10 per group) were deeply anesthetized with pentobarbital (50 mg kg
À1
) and perfused transcardially with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Coronal 50-mm-thick brain sections were cut in a vibratome and collected in phosphate-buffered saline. Sections were incubated with 100% methanol and 0.03% H 2 O 2 to eliminate endogenous peroxidase, followed by incubation overnight at 4 1C with primary antibody in phosphate buffer-1% bovine albumin-1% Triton X-100. For immunocytochemistry of Ab plaques, a pre-treatment of 70% formic acid was used before incubation with anti-human Ab antibody (1:50, Dako clone 6F/3D, Glostrup, Denmark). After several washes in phosphate buffer, sections were incubated with a biotincoupled secondary antibody (1:500, Pierce, Rockford, IL, USA), followed by ABC amplification system (1:250, Pierce). For double immunofluorescence with Ab, astrogliosis was determined using anti-GFAP (1:1000, Dako) and microgliosis with anti-Iba1 (1:500, Wako, Chuo-ku, Osaka, Japan). Sections were then incubated with an Alexa-coupled secondary antibody (1:1000, Molecular Probes, Eugene, OR, USA). Omission of primary antibody was used as control. Confocal analysis was performed using a Leica (Wetzlar, Germany) microscope.
Plaque morphometry
In all, 1-4 vibratome brain sections (50 mm) were used to assess the density of Ab plaques. Analysis was performed using ImageJ software (NIH) on the parietal cortex and the hippocampus. Measurements were performed on images recorded with a Leica microscope using a Â 5 objective. In brief, images were previously converted to gray scale to improve the contrast between signal and noise. All pictures were measured separately applying the same threshold. Areas were measured inside a reference circle with a standard size of 300 mm 2 (see the study by Trejo et al. 12 for further details).
Behavioral tests
In the 'object recognition test', mice were placed in an arena (55 Â 40 Â 40 cm 3 ) in a room with dim lighting and constant background noise. Two different objects in the arena were used during the training phase. After a delay time, one object was changed with a new one. The aim was to test the animal's memory of the original object by comparing the amount of time spent exploring the novel object against that spent with the familiar one. Objects were thoroughly cleansed with 70% ethanol between trials to ensure the absence of olfactory cues. Before the experiment, mice were habituated to the arena in the absence of objects for 20 min per day on 2 consecutive days. On the day of testing, mice were left 10 min to explore. Retention tests were performed after the training session by placing mice back in the arena for a 10-min session and by randomly exchanging one of the familiar objects with a novel one. The time spent exploring each object was recorded, and the relative exploration of the novel object was expressed by a discrimination index = (tnovelÀtfamiliar)/(tnovel þ tfamiliar). Discrimination indices X0.2 were considered as efficient memory. Exploration of an object was defined as directing the nose toward the object at a distance of p1.5 cm and/or touching it with the nose or its vibrissae. Going around or sitting on the object was not considered exploratory behavior. In all, 10 mice were used for each group.
Y maze. Working memory was assessed by recording spontaneous alternation behavior in a Y maze. 13 The maze was made of black-painted wood and each arm was 25 cm long, 14 cm high, 5 cm wide and positioned at equal angles. Mice were placed at the end of one arm and allowed to move freely through the maze during an 8-min session. Arm entries were recorded visually. Arm entry was considered to be completed when the hind paws of the mouse were completely placed in the arm. Alternation was defined as successive entries into the three arms on overlapping triplet sets. Percentage alternation was calculated as the ratio of actual-to-possible alternations without repeated entries (defined as the total number of arm entries minus two), multiplied by 100.
Morris water maze. We followed procedures already described in detail. 14 In brief, after a 1 day habituation trial (day 0) in which preferences between quadrants in the different experimental groups were ruled out, animals learned to find a hidden platform over the next 1-6 days, through 4 trials per day, 60 s each trial, plus 20 s in the platform. If an animal failed to reach the platform, it was placed on it by the experimenter. Animals were then subjected to two trials on the seventh day, the first without the platform to assess possible differences in swimming speed and preference for the platform quadrant. In the second, a cued version protocol using a visible platform was conducted to determine sensorimotor and motivational status of animals. Mean escape latency was analyzed by two-way repeated-measures analysis of variance, whereas differences in the slope of the learning curve were determined using one-way analysis of variance.
In vitro experiments
À cells) were prepared as described previously. 6 In brief, postnatal (day 3-4) brains were dissected and immersed in ice-cold Dulbecco's modified Eagle's medium/F-12; Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum. The cortex and hippocampus were removed and cut into 1-mm pieces. Tissue fragments were dissociated mechanically, and the resulting cell suspension was centrifuged (1000 r.p.m./10 min) and plated in Dulbecco's modified Eagle's medium/F-12 with 10% fetal bovine serum, 5 Â 10 5 cells per well. Cultures were allowed to grow for 2 days. Pure neuronal cultures were obtained as described previously. 6 Pure microglial and oligodendroglia cultures were obtained as described in doi:10.1038/protex.2011.218. Human astrocytes (P10251) were purchased from ScienceCell (Carlsbad, CA, USA) and cultured following the manufacturer's instructions. Cells were treated with TNFa (20 ng ml
À1
, Sigma) and IGF-I (100 nM, PreProTech, Rocky Hill, NJ, USA) overnight. The calcineurin inhibitor cyclosporine (CsA, 500 nM, Calbiochem, Darmstadt, Germany) or the PPARg agonist pioglitazone (5 mM, Sigma) were added 1 h before TNFa and/or IGF-I. Dox (10 mg ml
) was added to the cultures of AIC brain cells 24 h before to inhibit expression of DCnA.
Transfections and gene reporter assays Cultured cells were electroporated using the Amaxa Nucleofector system (Lonza, Basel, Switzerland). In brief, astrocytes were placed in 0.1 ml nucleofection solution with either 2 mg pMAXGFP or plasmid DNA encoding the reporter gene p-nuclear factor-kB (NFkB)-secreted alkaline phosphatase. Mock transfection was performed with a pCMV vector and assays performed according to the manufacturer (Clontech, Mountain View, CA, USA). For luciferase assays, cells nucleofected with a reporter construct bearing six canonical FOXO-binding sites (6 Â DBE-luciferase) were co-electroporated with the construct pECEdominant-negative FOXO3 (DN-FOXO3). Luciferase counts were normalized using TK-Renilla luciferase. Luciferase activity was analyzed using dual luciferase assay kit according to the manufacturer (Promega, Madison, WI, USA). Luminescence was quantified using a Sirius Luminometer (Berthold Detection Systems, Pforzheim, Germany). PPARg activity was measured using the Cignal reporter (luc) assay (SABiosciences, Frederick, MD, USA) following the manufacturer's instructions. Luminescence was measured using a Multiskan Ascent V1.25 (ThermoElectron Corporation, Essex, UK). Luciferase and secreted alkaline phosphatase activities were expressed as fold increase with respect to control levels. For RNA interference experiments (Silencer small-interference RNA (siRNA) transfection II kit; Ambion, Austin, TX, USA), three different double-stranded CnA siRNAs (with sequences CnA1, 5 0 -GGAAGUGUUUGAUAAC GAU-3 0 ; CnA2, 5 0 -GGAAGGCAGGCUGGAAGAA-3 0 ; CnA3, 5 0 -GGAUUCUCACCACAACAU-3 0 ) were nucleofected into primary astrocytes. Seventy-two hours later, cultures were stimulated with TNFa (20 ng ml À1 ) overnight. Cells were lysed and Foxo3 activity measured. A non-targeting siRNA and a GAPDH (glyceraldehyde 3-phosphate dehydrogenase) siRNA were used as negative and positive controls, respectively. Assays were performed in triplicate.
Calcineurin activity
Various assays were performed. To test phosphatase activity of calcineurin, a commercial kit (Calbiochem) was used as described previously. 6 In brief, cells and brain tissue were homogenized in lysis buffer (50 mM Tris, 1 mM DTT, 100 mM EDTA, 100 mM EGTA and 0.2% Nonidet P-40, pH 7.5) containing a protease inhibitor cocktail (Roche, Basel, Switzerland). Free phosphate was removed from samples using a desalting column. Assays were run in 100 ml of buffer (200 mM NaCl, 100 mM Tris, 12 mM MgCl 2 , 1 mM CaCl 2 , 1 mM DTT and 0.05% Nonidet P-40, pH 7.5) with recombinant human calcineurin (50 U ml À1 ), calmodulin (25 mM) and 10 ml of the calcineurin-specific RII phosphopeptide. When indicated, EGTA was added (20 mM), and assays were incubated at 30 1C for 30 min. Phosphatase activity was measured by detection at 620 nm of free phosphate. Assays were performed in duplicate at each time point in three separate experiments.
To determine in vivo dephosphorylation of Foxo3 by calcineurin, astrocytes were treated with TNFa (20 ng ml
À1
) and different doses of CsA (0.03-4 mM) and analyzed by western blotting using anti-phosphoThr 32 and phospho-Ser 253 -Foxo3 antibodies. In additional experiments, astrocytes were nucleofected with CnA siRNA before western blot analysis of phosphoFoxo3 residues. To analyze in vitro dephosphorylation of Foxo3 by calcineurin, cell extracts obtained from astrocytes stimulated with TNFa were prepared in phosphate assay buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.25% Nonidet P-40, 1 mm phenylmethylsulfonyl fluoride and protease inhibitor cocktail) and incubated on ice for 30 min. Cell lysates were centrifuged at 12 000 Â g for 10 min at 4 1C, and the supernatant was further incubated at 30 1C for 20 min with or without CsA (2 mM). Thereafter, supernatants were analyzed by western blot as described above. Re-blotting of membranes with antiFoxo3 was performed for loading control. Experiments were run in triplicate.
Chromatin immunoprecipitation assays
Cells growing in p150 dishes were washed twice in serum-free medium and treated for 2.5 h with 2.5 mM a-amanitin. Cells were washed, treated with TNFa (20 ng ml
À1
) and fixed with 1% formaldehyde for 15 min at 37 1C. The chromatin immunoprecipitation assay kit from Upstate (Billerica, MA, USA) was used. 0 -TACTAGCGGT TTTACGGGCG-3 0 (forward) and 5 0 -TCGAACAGGAGG AGCAGAGAGCGA-3 0 (reverse), which amplify the GAPDH promoter (À460/À318). The latter was used as an internal positive control using the RNA polymerase II antibody. Amplified fragments were resolved on 1% agarose gels and visualized with ethidium bromide.
Immunoassays
Cells or brain hemispheres were homogenized in icecold buffer consisting of 10 mM Tris HCl, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1% Triton X-100, 1% Nonidet P-40, 400 mM sodium orthovanadate and protease inhibitors (200 mM PMSF, protease inhibitor cocktail (Sigma). Nuclear protein was extracted using the NE-PER nuclear and cytoplasmic extraction kit (Pierce). The concentration of protein was determined using a protein assay (Bio-Rad, Hercules, CA, USA). Western blot and immunoprecipitation were performed as described previously. 6 Antibodies used include antiNFkB p65, anti-PPARg, anti-Foxo3a, anti-phosphoSer , anti-GFAP (Sigma) and bIII-tubulin (Promega). Membranes were reblotted with either the same antibody used for immunoprecipitation or with b-actin (Sigma) or lamin A þ C (Abcam) to normalize for protein load. Levels of the protein under study were expressed relative to protein load. Densitometric analysis was performed using Quantity One software (Bio-Rad). A representative blot is shown from a total of at least three independent experiments. Ab and Ab were quantified in brain hemispheres homogenates by sandwich enzyme-linked immunosorbent assay using Ab as a standard following manufacturer's instructions (Genetics, Schlieren, Switzerland). Absorbance was measured at 450 nm.
Quantitative PCR array First-strand cDNA was synthesized from RNA using the RT 2 First-Strand Kit (SABiosciences). Mouse inflammatory cytokines and growth factors PCR array (SABiosciences) were used to profile the cytokine and growth factor expression in brain hemispheres following instructions from the manufacturer. The DDC t method was used to analyze the expression level of each gene using the Data Analysis Template provided by SABiosciences. After PCR, the dissociation curve for each gene was examined to exclude those with nonspecific amplification or with undetectable expression. Quantitative real-time PCR was performed using an ABI Prism 7500 detection System (Applied Biosystems, Carlsbad, CA, USA).
Statistics
Statistical analyses were performed with a t-test when comparing two groups and a two-way analysis of variance for comparing multiple groups. Statistical significance was established when P < 0.05. Results shown are mean ± s.e.m.
Results
IGF-I inhibits calcineurin dephosphorylation of Foxo 3 in response to TNFa in astrocytes
In a previous study, we found that IGF-I antagonizes the proinflammatory actions of TNFa in astrocytes and that the phosphatase calcineurin was involved in an ambivalent manner in this antagonistic interaction. 6 Thus, in quiescent astrocytes, calcineurin is potently activated by TNFa and modestly stimulated by IGF-I. When both factors are added together, its activity remains increased (Figure 1a ), whereas its levels remain unaffected at all times (Supplementary Figure 2a) . Antagonistic actions of IGF-I were seen downstream of calcineurin activation. IGF-I blocked TNFa-induced association of calcineurin with NFkB ( Figure 1b) , a canonical proinflammatory transcription factor activated by TNFa. As a consequence of this blockade, the activity of NFkB was inhibited. Proinflammatory genes downstream of NFkB such as Cox2 were no longer stimulated ( Supplementary  Figures 2b and c) . These confirms previous observations 6 and unveils an antagonism of IGF-I on TNFa inflammatory signaling by modulating this calcineurin/NFkB pathway.
As activation of calcineurin does not determine whether it associates with NFkB, we searched for a mechanism that could explain this divergence. We focused on the transcription factor Foxo. These transcriptional modulators are stimulated by TNFa, 15 inhibited by IGF-I through Akt-mediated phosphorylation, 16 and display complex functional relations with calcineurin. 17, 18 Indeed, the activity of Foxo3, the most abundant type of Foxo in the brain, showed a differential response to TNFa and IGF-I in astrocytes (summarized in Figure 1c ). Foxo3 was potently activated by TNFa and IGF-I antagonized this effect (Figure 1d ). IGF-I did not affect baseline Foxo activity (Figure 1d ). On the basis of these observations, we speculated that a TNFa/IGF-I-regulated interaction between Foxo and calcineurin could In human astrocytes, calcineurin also associates with Foxo3 in response to TNFa. (n) Calcineurin needs to be active to associate with Foxo3 in response to TNFa as their co-immunoprecipitation is abolished by CsA. Representative blots are shown (at least three experiments in each condition); **P < 0.01 and ***P < 0.001 vs respective controls. CsA, cyclosporine; IGF-I, insulin-like growth factor I; NFkB, nuclear factor-kB; siRNA, small-interference RNA; TNFa, tumor necrosis factor-a.
act as a molecular switch between inflammation and its resolution. As Foxo is inhibited by phosphorylation, we speculated that calcineurin may be dephosphorylating Foxo3 in response to TNFa. Thus, both active calcineurin and Foxo3 would be required for inflammation to proceed.
We found that calcineurin is essential to activate Foxo3 by TNFa. Inhibition of calcineurin with CsA (Figure 1e) or transfection of astrocytes with a calcineurin siRNA (Supplementary Figure 2d) significantly impaired Foxo activation by TNFa. In contrast, Foxo3 was not involved in TNFa activation of calcineurin. In the presence of a dominantnegative Foxo3 (DN-Foxo), TNFa still activated CnA (Figure 1f) . Accordingly, inhibition of CnA with CsA or blocking its expression with siRNA inhibited TNFa-induced dephosphorylation of Foxo3 at Thr 32 and Ser 253 residues. These two residues are targeted by Akt to inactivate Foxo. 16 Dephosphorylation of Foxo3 by calcineurin was seen both in cell extracts and in cultured astrocytes (Figures 1g-i) .
Furthermore, calcineurin associated with Foxo3 in response to TNFa and dissociated from Foxo3 by IGF-I (Figures 1j and k) . Association of calcineurin with Foxo3 involves its catalytic domain. In astrocytes transfected with a truncated calcineurin harboring only the phosphatase domain (DCnA), coimmunoprecipitation with Foxo3 in response to TNFa was preserved (Figure 1l ). In turn, the DNAbinding domain of Foxo3 was not involved in the interaction because a truncated form consisting only of this domain did not immunoprecipitate with calcineurin after TNFa (not shown). These data suggest that Foxo3 binds to the catalytic domain of calcineurin to become dephosphorylated at regions not involving its DNA-binding domain. Interaction between Foxo3 and calcineurin was not speciesspecific as co-immunoprecipitation was also observed in human astrocytes exposed to TNFa (Figure 1m ). In addition, co-immunoprecipitation of calcineurin with Foxo3 was abolished by CsA (Figure 1n) , further supporting the need of this interaction in the activation of Foxo3 by calcineurin.
IGF-I antagonizes calcineurin activation of Foxo3 through PPARg
Next, we searched for mechanisms underlying the antagonistic effect of IGF-I on the association of Foxo3 with CnA. Calcineurin is required to activate NFkB by TNFa in astrocytes; 6 hence, we could block this activation using calcineurin siRNA (Figure 2a) or CsA (not shown). We observed that Foxo3 is also involved in TNFa activation of NFkB. Abrogation of Foxo3 activity with DN-Foxo3 abrogated activation of NFkB by TNFa (Figure 2a) . Accordingly, activation of target genes of NFkB such as Cox2 depended not only on calcineurin but also on Foxo activity (Supplementary Figures 2e and f) . As calcineurin associates with NFkB and with Foxo3 after stimulation with TNFa, we speculated that the three proteins were forming a complex to direct NFkB transcriptional activity in the cell nucleus. Indeed, upon stimulation of astrocytes with TNFa, calcineurin was found in the cell nucleus (Figure 2b ). This effect was reverted by IGF-I. Furthermore, the three proteins interact at NFkB target genes after stimulation with TNFa, as determined by chromatin immunoprecipitation assays with the putative Cox2 promoter region that binds NFkB (Figure 2c) .
In a previous study, we found that IGF-I blocked NFkB activity in TNFa-stimulated astrocytes by recruiting PPARg, 6 a transcriptional modulator with anti-inflammatory properties that inhibit NFkB. 19 We now confirmed and extended these observations. Stimulation of TNFa-stimulated astrocytes with IGF-I elicited the association of PPARg with NFkB and calcineurin, whereas Foxo3 was no longer present in the complex (Figure 2d ). In parallel, PPARg became sumoylated (Figure 2e) , a pre-requisite to trans-repress NFkB. 19 That PPARg activity is essential in this process was confirmed using the PPARg agonist pioglitazone in astrocytes exposed to TNFa. Pioglitazone inhibited Foxo activity induced by this cytokine (Figure 2f ). Recruitment of PPARg to the NFkB complex by IGF-I involved extracellular signal-regulated kinases (Figure 2g ), a canonical pathway downstream of the IGF-I receptor. The effect of IGF-I was abrogated with the extracellular signal-regulated kinase inhibitor U0126.
As the microglia is a major determinant of inflammation in AD pathology, 20 we examined whether TNF/ IGF-I could also modulate this calcineurin/NFkB/ Foxo3/PPARg pathway in this cell type. Calcineurin did not co-immunoprecipitate with these transcriptional modulators in cultured microglia (not shown).
Modulation of the calcineurin pathway in astrocytes affects AD pathology in mice We determined whether the association of calcineurin with NFkB seen in cultured astrocytes exposed to TNFa (Figure 1b) was present in vivo in the brain of APP/PS1 mice. Importantly, the levels of TNFa mRNA are markedly increased in these mutant mice, a wellestablished model of AD pathology (Supplementary Table 1 ). We found that although total brain levels of CnA remain normal (Supplementary Figure 2g) , calcineurin co-immunoprecipitated with NFkB only in the APP/PS1 brains (Figure 3a) . APP/PS1 mice show prominent increases in many other proinflammatory cytokines (Supplementary Table 1) , which confirms the reported brain inflammation in AD-like mice. 21 As the expression of constitutively active calcineurin (DCnA) in astrocytes mimics the antagonistic effect of IGF-I on inflammatory signaling, 6 we bred AIC mice with APP/PS1 mice to regulate the expression of DCnA in astrocytes. Thus, disease progress was ascertained in the presence or absence of DCnA expression in astrocytes of the compound AIC Â APP/ PS1 line (AICAP mice, Figure 3b ). AICAP mice receiving dox (dox) during the first 6 months of life to restrain expression of DCnA displayed the same degree of amyloid load as the parent APP/PS1 line with or without dox. Notably, AICAP mice expressing DCnA in astrocytes (without dox in their drinking water) showed a marked reduction in plaque load (Figure 3c , P < 0.001 vs APP/PS1 or AICAP þ dox). Time-course analysis of amyloid burden revealed a protracted appearance of amyloid plaques in AICAP mice (Supplementary Figure 3) . Furthermore, levels of Ab peptides 1-40 and 1-42 determined by enzymelinked immunosorbent assay were markedly reduced even at relatively late stages (14 months) of the disease in AICAP mice as compared with APP/PS1 mice (Table 1) . mRNA levels of the Ab proteases neprilysin or insulin-degrading enzyme, or of the amyloidogenic secretase BACE remained unaltered in AICAP mice (not shown).
Reactive gliosis (Figure 4a , green) surrounding Ab deposits (Figure 4a , red) and characterized with cellspecific markers such as GFAP (astroglia) and Iba1 (microglia) appeared reduced in AICAP mice as compared to APP/PS1 and AICAP þ dox mice. AICAP mice harbor smaller and less plaques with less reactive astrocytes surrounding them. Accordingly, expression of the astrocytic marker GFAP, and the microglial marker Cd11b, was significantly reduced in AICAP mice, whereas expression of the microglia cytokine TNFa was also markedly attenuated (Figure 4b ). In addition, AICAP mice showed preserved cognition in a battery of tests usually used to determine cognitive status in AD mice such as object recognition, or the Y and Morris mazes (Figures 5a-c) . Thus, the relatively low amount of plaques and Ab peptides seen in AICAP mice did not interfere with cognition. Although APP/ PS1 and AICAP þ dox mice show cognitive losses as early as 3-4 months of age, in AICAP mice, cognition was preserved at all times (not shown). Neither the PI3K inhibitor Ly 294002 nor the p38MAPK inhibitor SB203580 interferes with the action of IGF-I. Representative blots. At least three independent experiments per group are shown. *P < 0.05 and ***P < 0.001 vs control. ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IGF-I, insulin-like growth factor I; NFkB, nuclear factor-kB; PPARg, peroxisome proliferator-activated receptor-g; siRNA, small-interference RNA; TNFa, tumor necrosis factor-a.
To ascertain the effect of DCnA in regulating disease progress, its expression was modulated by administering dox to AICAP mice at varying times. When mice were maintained without dox during the first 5 months of life ('off' period) to allow DCnA expression and thereafter received dox for 5 additional months to inhibit it ('on' period), they showed the same degree of amyloid load and cognitive deterioration than did age-matched APP/PS1 mice (Figure 5d ). Conversely, when the DCnA expression was allowed after 5 months of treatment with dox by withdrawing the drug (ON-OFF), AICAP mice maintained without dox for 5 months showed significantly lower levels of amyloid plaques and preserved cognition than did age-matched APP/PS1 mice (Figures 5d-f) . The latter suggested that DCnA expression in astrocytes at times when the disease has already manifested is still beneficial (see Supplementary Figure 3 for comparison of amyloid load). Collectively, these data indicate that regulation of astrocyte calcineurin is a major determinant of AD pathology.
Importance of the calcineurin pathway in AD Next, we checked whether the divergent calcineurin pathway seen in vitro was also present in vivo. Calcineurin/Foxo3 complexes were detected in the APP/PS1 mice brains, but not in wild-type littermates (Figure 6a ), conforming with high TNFa levels in the brain of these mice. In turn, APP/PS1 mice treated for 3 months with a subcutaneous depot of IGF-I showed a diminished interaction between Foxo3 and calcineurin (Figure 6a ), without altering total CnA levels (Supplementary Figure 4a) . IGF-I treatment also reduced the interaction of NFkB with CnA and Foxo3, whereas increased the interaction with PPARg (Figure 6b ). At the same time, APP/PS1 mice treated with IGF-I had markedly reduced pathology (Supplementary Figure 4) , which corroborates previous reports of the beneficial effects of systemic IGF-I in AD mice 1, 14 and further suggests that progress of the disease involves modulation of this calcineurin pathway.
In agreement with these observations in IGF-Itreated APP/PS1 mice, AICAP mice showed CnA/Foxo3 complexes in their brains only when receiving dox (Figure 6c ). That this complex is related to AD pathology was indirectly confirmed by the observation that in an area devoid of plaques such as the cerebellum, this complex was not found (Figure 6d ). Other actions of IGF-I were also mimicked by DCnA expression in AICAP mice. Thus, phosphorylated Foxo3, an inverse index of the phosphatase activity of calcineurin (see Figure 1) and of Foxo activation, was increased in AICAP, APP/ PS1 þ IGF-I, or AIC mice, but not in APP/PS1 or AICAP þ dox mice (Figures 6b and e) . Furthermore, levels of Cox2 and iNOS2 (downstream of NFkB activation) were increased only in APP/PS1 and AICAP þ dox mice but not in AICAP or APP/ PS1 þ IGF-I mice (Figure 6f) .
We next explored the effect of in vivo DCnA expression on PPARg. This transcription factor was found associated with NFkB only when DCnA was expressed, that is, in AIC or AICAP mice, but not in APP/PS1 or AICAP þ dox mice (Figure 6g) . Furthermore, only in AICAP mice, PPARg was sumoylated (Figure 6h) , associated with CnA and its activity increased (Figure 6i ). Total levels of PPARg in AICAP mice remained similar to other mice (not shown). Conversely, interaction of calcineurin, Foxo3 and NFkB on the Cox2 promoter using chromatin immunoprecipitation was observed only when DCnA was not expressed; that is, in AICAP þ Dox mice (Figure 6j) .
In vitro expression of DCnA in astrocytes not only makes them refractory to TNFa proinflammatory action but also increases the production of IGF-I. 6 Thus, we analyzed IGF-I expression in AICAP mice with or without dox and found that when DCnA expression is allowed, high levels of IGF-I together with several other growth factors are observed in the brain (Supplementary Table 2 ). We confirmed high protein levels of the three growth factors with the highest expression: IGF-I, IGF-II and FGF-8 ( Figure 6k ). Increased brain IGF-I levels in AICAP mice devoid of AD pathology agrees with the protective effect exerted by exogenous administration of IGF-I to APP/PS1 mice.
To ascertain the relevance of these findings to human disease, we determined whether brains from AD patients display features of this pathway. We determined interactions of calcineurin with Foxo3 and NFkB because they herald the proinflammatory cascade in astrocytes. After immunoprecipitation of AD brain extracts with the corresponding antibodies, we detected complexes of calcineurin Figure 4 Gliosis is reduced in AICAP mice. (a) Reactive astrogliosis was determined by immunocytochemistry of the astrocytic marker GFAP (green). Reactive microglia was detected with the specific marker Iba1 (green). The number of GFAP þ and Iba þ cells was reduced in proportion to the reduction in Ab plaques seen in AICAP mice as compared with APP/ PS1 or AICAP þ dox mice. (b) Astrogliosis was quantified by measuring brain levels of GFAP mRNA, whereas microgliosis was determined measuring brain Cd11b and TNFa mRNAs. All these markers of gliosis were reduced in AICAP mice. *P < 0.05; **P < 0.01 vs AICAP þ dox (n = 6). TNFa, tumor necrosis factor-a.
with Foxo3 and with NFkB only in AD brains with overt pathology (Figures 7a and b) . At early stages (Braak stages I and II), the complexes were absent. Furthermore, the cerebellum from AD patients, an area usually free of pathology showed no complexes (Figures 7a and b) .
Discussion
Several conclusions may be drawn from these observations. First, divergent modulation of astrocyte calcineurin by neuroprotective factors such as IGF-I or proinflammatory cytokines such as TNFa determines progression of AD pathology in mice. Therefore, the observed imbalance between these regulatory factors in AD probably drives human pathology. Second, the proposed role of astrocytes as amplifiers of inflammatory cascades in AD 20 seems critical to disease progress in AD mice. Astrocytes are targeted by inflammatory signals produced by activated microglia, such as TNFa that direct calcineurin toward NFkB-dependent inflammatory cascades that likely contribute to the inflammatory phenotype seen in AD. As calcineurin interacts with Foxo3 and NFkB in human AD brains in a similar manner, our observations are relevant to human pathology and further support a therapeutic use of IGF-I in this disease.
These results also suggest that specific growth factors may constitute endogenous defense mechanisms against AD pathology. In agreement with this possibility is the observation of decreased IGF-I function in AD brains. 2, 22 Although the mechanism underlying a putative protective role of other growth factors (Supplementary Table 2 ) in AD require further work, our results indicate that IGF-I is neuroprotective at least in part, by abolishing the interaction induced by TNFa in astrocytes between calcineurin and Foxo3. Through a two-sided process, IGF-I induces phosphorylation of Foxo3 through Akt and association of PPARg with calcineurin/NFkB through extracellular signal-regulated kinases. The net effect is that Foxo3 no longer associates with calcineurin/ NFkB and inflammation is blocked, Ab levels reduced and growth factor expression increased ( Figure 7c) . As discussed below, this neuroprotective loop probably involves PPARg and is mimicked by DCnA. These observations accord with reduced amyloidosis in AD mice after inhibition of TNFa receptors. 23 Disturbed Ca þ þ regulation has recently been shown in astrocytes of AD mice. 24 These disturbances likely affect calcineurin because this phosphatase is regulated by Ca þ þ . A role of CnA in AD pathology is highlighted by the fact that expression of a constitutively active calcineurin in astrocytes of APP/PS1 (the AICAP mouse) substantially abrogates AD pathology. Expression of DCnA in AICAP mice is associated with reduced amyloidosis and inflammation, whereas AICAP þ dox mice, similar to APP/PS1 mice, have pronounced amyloidosis and an inflammatory phenotype. As amyloidosis and inflammation are closely intertwined in AD, 8 and inflammatory injuries trigger amyloidosis in normal brains, 25 we hypothesize that amyloidosis is reduced in AICAP mice because inflammation is resolved. Hence, although high levels of Ab in AD mice will elicit an inflammatory response that in turn will feed back to increase amyloidosis, in AICAP mice, this vicious cycle will be canceled. A corollary of this notion is that inflammation is a driving force in AD, or, in other words, the postulated 'second hit' required for neurodegeneration. 26 There is accumulating evidence of an important role of calcineurin in AD. Earlier reports of increased brain calcineurin mRNA and activity in AD 27, 28 together with decreases in its protein levels 29 hinted at functional disturbances of this phosphatase. More recent observations pointing to high calcineurin immunoreactivity in astrocytes of AD mice, 30 higher levels of calcineurin in nuclear extracts of AD brains 31 together with overactive calcineurin in neurons, 32 provide a robust rationale for the involvement of this phosphatase in AD pathology. As TNFa and Ab stimulate calcineurin in astrocytes, 6, 33 it is probable that its activity is upregulated in the nucleus of AD astrocytes. 31 Collectively, these findings indicate that through different pathways, dysregulated calcineurin activity in astrocytes and neurons 32 contributes to disease load. Although inhibition of calcineurin in neurons may be beneficial, in the case of astrocytes, calcineurin activity should be re-directed toward resolution of inflammation rather than merely inhibiting it.
Transcription factors of the Foxo family, which form a part of the canonical signaling of insulin and IGF-I, have been classically related to stress responses, 34 although several observations support a functional relationship between calcineurin and Foxo. Thus, Foxo3 was reported to inhibit calcineurin 18 and dissociate it from a complex with Akt. 35 However, in astrocytes, Foxo3 activity did not affect CnA activation in response to TNFa (Figure 1e ). Conversely, previous reports indicate that CnA may regulate Foxo3 activity in a manner similar to what we observed. Thus, CnA stimulates Foxo3 in neurons 36 as seen by us in astrocytes. Intriguingly, a natural constitutively active isoform of calcineurin (CnAb1), which is upregulated by a muscle isoform of IGF-I, resolved inflammation by inhibiting Foxo3 in injured muscle. 17 This opposite role of CnAb1 agrees with what we see with DCnA in AICAP mice. Collectively, these findings indicate a cell-context and isoform-dependent functional relationship between Foxo and CnA. We speculate that in AD, inhibition of Foxo3 may produce beneficial effects at least in part by inhibiting inflammation in astrocytes.
Recruitment of PPARg seems a key step toward neuroprotection in this dual calcineurin pathway. PPARs reduce glial inflammation, 37 trans-repress NFkB activity 19 and interact with NFkB to inhibit it. 38 This agrees with our present observations in astrocytes. In response to either IGF-I treatment or expression of DCnA, PPARg becomes sumoylated and , and in parallel recruits PPARg (through ERKs) that becomes sumoylated and active to represses NFkB activity. This pathway resolves inflammation, decreases Ab levels and stimulates the production of neuroprotective growth factors through as yet unknown mechanisms. Similarly to the vicious cycle established by cytokines in inflammatory pathways, the neuroprotective pathway may establish a virtuous cycle, whereby production of factors such as IGFs feed onto anti-inflammatory signaling. Constitutively active calcineurin (DCnA) mimics the action of IGF-I by directly stimulating PPARg association with the CnA/NFkB complex. We speculate that lack of the autoregulatory moiety in DCnA either increases the affinity toward PPARg or decreases its affinity toward Foxo3. AD, Alzheimer's disease; ERK, extracellular signal-regulated kinase; IGF-I, insulin-like growth factor I; NFkB, nuclear factor-kB; PPARg, peroxisome proliferator-activated receptor-g; TNFa, tumor necrosis factor-a.
binds to the calcineurin/NFkB complex displacing Foxo3 from it. Sumoylation of PPARg is required for trans-repression of NFkB. 19 As phosphorylation is an important modulator of PPARg sumoylation and activity, 39 we speculate that calcineurin regulates PPARg activity through dephosphorylation. Akin to the inhibitory effect of CnAb1 on Foxo, which inhibits inflammation in muscle, 17 DCnA likely inhibits Foxo in astrocytes by recruiting PPARg. Support for this view is that the PPARg agonist pioglitazone mimics the action of DCnA (Figure 2f) . The net effect is that DCnA impedes activation of NFkB by TNFa (produced at high levels in APP/PS1 mice) and proinflammatory signaling is abrogated. However, PPARg agonists with early promising results in clinical trials in AD 40 did not show efficacy in later trials. 41 Our result indicate that PPARg activity should be specifically regulated in astrocytes to be beneficial.
Homeostatic inflammation includes its eventual resolution. We speculate that activation of Foxo3 by TNFa/Ab-activated calcineurin is the proinflammatory arm in astrocytes that remains activated in AD because of a vicious cycle with high levels of TNFa and Ab. Indeed, calcineurin activity is increased in AD, 28 and its inhibition is sufficient to restore cognitive performance in AD mice. 42 Conversely, DCnA expression in AICAP mice or administration of IGF-I promotes resolution of the inflammatory response. The opposite role of DCnA, reminiscent of the natural isoform CnAb1 (see above), suggests a gain of function of DCnA probably due to the absence of the auto-regulatory moiety that allows constitutive recruitment of PPARg, as observed in AIC and AICAP mice ( Figure 6g ). As CnAb1 is present in the brain, 17 its potentiation may be a result of therapeutic interest. The absence of inflammation in AICAP mice probably involves increased levels of brain IGF-I (Figure 6h and  Supplementary Table 2 ) by counteracting the action of TNFa. Calcineurin promotes IGF-I expression in muscle through nuclear factor of activated T-cells, 43 a pathway also seen by us in astrocytes. 6 Thus, activation of calcineurin may mediate upregulation of growth factors such as IGFs that would contribute to the resolution of inflammation, protection against cognitive deterioration 12, 44 and reduction of Ab levels 1, 45 in AICAP mice ( Figure 7c ). As already mentioned, the role of IGF-I in AD is controversial. Both beneficial 1 and detrimental 3, 4 actions of this neurotrophic pathway has been reported. Apart from the different experimental approaches used in each case, and alternative explanations such as that deletion of insulin and IGF-I receptors produce a counter-intuitive antiapoptotic effect, 46 all current explanations rely on a neuro-centric view of AD. It may well be that the actions herein described of IGF-I on reactive astrocytes participate in the beneficial effect of this growth factor in AD and most significantly, it would mean that IGF-I is acting only in the diseased brain. Certainly, IGF-I uncouples calcineurin from Foxo3 only in astrocytes stimulated with TNFa, which can be considered an emergent property as this interaction is not seen in quiescent astrocytes.
In summary, our results indicate an important role in AD of astrocyte calcineurin and describe an underlying competitive mechanism between TNFa and IGF-I through the antagonistic interaction of the phosphatase calcineurin with the transcription factors Foxo3 and PPARg.
Conflict of interest
ITA has shares in a spin-off company devoted to the use of IGF-I in neurodegenerative diseases.
